Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse

INTRODUCTION: 25% of Stage III colon cancer patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery and chemotherapy. We hypothesise that sub-types of MRD, defined by circulating tumour cells (CTCs) and bone marrow micro-metastasis (mM) have different types an...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Nigel P, Aedo, Sócrates, Villalon, Ricardo, López, Marco Antonio, Minzer, Simona, Muñoz, Lorena, Orrego, Shenda, Contreras, Luis, Arzeno, Lucas, Guzman, Eghon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605629/
https://www.ncbi.nlm.nih.gov/pubmed/31281432
http://dx.doi.org/10.3332/ecancer.2019.935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605629/
https://www.ncbi.nlm.nih.gov/pubmed/31281432
http://dx.doi.org/10.3332/ecancer.2019.935

Ejemplares similares